China Resources Boya Bio pharmaceutical Group Co Ltd (300294) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of China Resources Boya Bio pharmaceutical Group Co Ltd stock ¥7.43, price ¥14.25, that is 47.9% below the price, quality 45 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range ¥13.63 – ¥54.29 · fair‑value band ¥5.34 – ¥9.52 · the ¥14.25 price screens above the ¥7.43 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow China Resources Boya Bio pharmaceutical Group Co in your weekly email
Every Wednesday you see whether China Resources Boya Bio pharmaceutical Group Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China.
Show moreShow less
It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound bone peptide, oxytocin, heparin sodium injection, posterior pituitary, and carboprost tromethamine injection.
In addition, it engages in research, development, production, and sales of anti-infective, diabetes, and cardiovascular drugs.
The company was formerly known as Boya Bio-pharmaceutical Group Co., Ltd. and changed its name to China Resources Boya Bio-pharmaceutical Group Co.,Ltd. The company was founded in 1993 and is based in Fuzhou, China.
Stock analysis
China Resources Boya Bio pharmaceutical Group Co Ltd (300294) currently trades at ¥14.25, while our model-based Fair Value estimate is ¥7.43, 48% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥8.50 per share, and 1 of the 16 models we run sit above the ¥14.25 price.
Bear case: the Dividend Discount group reads lowest at ¥4.46, and 15 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥5.34 (bear) to ¥9.52 (bull), the price of ¥14.25 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
China Resources Boya Bio pharmaceutical Group Co Ltd reported revenue of 2.0B CNY in FY2025 versus 2.7B CNY in FY2021, a compound −6.2%/yr. Reported net income was 113M CNY in FY2025, compounding −24.4%/yr from FY2021.
Key figures
Market cap 7.2B CNY (≈ $1.1B) Small · P/S ratio 4.26 · EPS (TTM) ¥−0.3400 · Dividend yield 0.5% · Net margin 5.5% · Return on equity −0.8% · Return on assets (EBIT) 5.2% (5-year average) · Operating margin −1.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −48%, 300294 screens richer than that median.
Fair Value models
Bear¥5.34Fair Value ¥7.43Bull¥9.52
Price ¥14.25 · Downside -47.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−21.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−22.3%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−22.3% vs −6.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 13%
Compare China Resources Boya Bio pharmaceutical Group Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score45 · Above median
Fair Value upside−47.9% · Above median
Profitability
Return on assets1.3% · Above median
Net margin (12 months)−3.6% · Below median
Operating margin (12 months)−1.2% · Below median
Growth and dividend
Revenue growth (quarter YoY)−31.7% · Bottom 25%
Dividend yield (12 months)0.5% · Below median
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.97× · Cheapest 25%
P/S (12 months)4.24× · Cheaper than median
EV/EBITDA33.5× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)10· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "China Resources Boya Bio pharmaceutical Group Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300294
Frequently asked questions
Is China Resources Boya Bio pharmaceutical Group Co Ltd (300294) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ¥7.43 versus a price of ¥14.25, about 48% lower (overvalued).
What is the fair value of 300294?
Our model-based fair value for China Resources Boya Bio pharmaceutical Group Co Ltd is ¥7.43 (as of Nov 5, 2026), built from audited fundamentals. The current price: ¥14.25.
What is the quality score of 300294?
China Resources Boya Bio pharmaceutical Group Co Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
Our model-based price target is the fair value of ¥7.43 (as of Nov 5, 2026) from 16 valuation models. Cautious scenario ¥5.34, optimistic scenario ¥9.52. It is a calculation from audited fundamentals, not an analyst target.
What is the China Resources Boya Bio pharmaceutical Group Co Ltd stock forecast for 2026?
Our models put fair value at ¥7.43, about 48% lower versus a price of ¥14.25 (overvalued). Cautious scenario ¥5.34, optimistic scenario ¥9.52. The calculation is refreshed regularly with new filings.
What is the revenue of China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
China Resources Boya Bio pharmaceutical Group Co Ltd reported trailing-twelve-month revenue of about 1.7B CNY (latest available figure, as of Nov 5, 2026).
Does China Resources Boya Bio pharmaceutical Group Co Ltd pay a dividend?
China Resources Boya Bio pharmaceutical Group Co Ltd currently shows a dividend yield of 0.51% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of China Resources Boya Bio pharmaceutical Group Co Ltd (300294) and when is the ex-dividend date?
China Resources Boya Bio pharmaceutical Group Co Ltd pays a dividend of ¥0.073 per share a year, a dividend yield of 0.5%. The last ex-dividend date was May 20, 2026. A dividend has been paid every year since at least 2012. The payout ratio is 32.7% of earnings. Our assessment: Token dividend. At a yield of 0.5% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.5% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For China Resources Boya Bio pharmaceutical Group Co Ltd it is ¥7.43 per share (as of Nov 5, 2026), against a price of ¥14.25. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is China Resources Boya Bio pharmaceutical Group Co Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 300294 trades above its calculated fair value: price ¥14.25, fair value ¥7.43, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300294?
No. The price is what the market pays today (¥14.25); the fair value is what the company's own numbers justify (¥7.43). For China Resources Boya Bio pharmaceutical Group Co Ltd the two are ¥6.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is China Resources Boya Bio pharmaceutical Group Co Ltd worth?
The market values China Resources Boya Bio pharmaceutical Group Co Ltd at about 7.2B CNY (market capitalisation, as of Nov 5, 2026). Per share that is ¥14.25; our models calculate a fair value of ¥7.43 per share.
What do the bullish and bearish scenarios say about 300294?
Our models span a range for China Resources Boya Bio pharmaceutical Group Co Ltd: cautious scenario ¥5.34, base ¥7.43, optimistic ¥9.52 per share (as of Nov 5, 2026, price ¥14.25). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
Balance-sheet figures for China Resources Boya Bio pharmaceutical Group Co Ltd (as of Nov 5, 2026): return on equity −0.8%, debt of 0.01 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 300294 from its 52-week high?
China Resources Boya Bio pharmaceutical Group Co Ltd trades at ¥14.25, about 44% below its 52-week high of ¥25.36 and 5% above the low of ¥13.63 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥7.43 is for.
Which stocks are comparable to China Resources Boya Bio pharmaceutical Group Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is China Resources Boya Bio pharmaceutical Group Co Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price ¥14.25, calculated fair value ¥7.43 (−48%), Quality Score 45/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300294 calculated?
We run China Resources Boya Bio pharmaceutical Group Co Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥7.43 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. China Resources Boya Bio pharmaceutical Group Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
The closing price on Nov 6, 2026 was ¥14.25. Our model-based fair value is ¥7.43, about 48% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with China Resources Boya Bio pharmaceutical Group Co Ltd right now?
The price sits above even our optimistic bull case (¥9.52). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts.
Where does the earnings growth of China Resources Boya Bio pharmaceutical Group Co Ltd (300294) come from?
Earnings per share at China Resources Boya Bio pharmaceutical Group Co Ltd grew −1.3 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.6 %, EBIT margin −6.5 %, tax rate −0.4 %, residual (interest, one-offs) −2.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of China Resources Boya Bio pharmaceutical Group Co Ltd
How large is the market capitalisation of China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
The market capitalisation of China Resources Boya Bio pharmaceutical Group Co Ltd is 7.2B CNY (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
The price-to-sales ratio of China Resources Boya Bio pharmaceutical Group Co Ltd is 4.26 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
Earnings per share at China Resources Boya Bio pharmaceutical Group Co Ltd are ¥−0.3400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
The dividend yield of China Resources Boya Bio pharmaceutical Group Co Ltd is 0.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
The net margin of China Resources Boya Bio pharmaceutical Group Co Ltd is 5.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
The return on equity (ROE) of China Resources Boya Bio pharmaceutical Group Co Ltd is −0.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
On an EBIT basis the return on assets of China Resources Boya Bio pharmaceutical Group Co Ltd is 5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
The operating margin of China Resources Boya Bio pharmaceutical Group Co Ltd is −1.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
Revenue at China Resources Boya Bio pharmaceutical Group Co Ltd is growing −31.7% versus a year earlier (3y avg −9.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at China Resources Boya Bio pharmaceutical Group Co Ltd (300294)?
Earnings per share at China Resources Boya Bio pharmaceutical Group Co Ltd are growing −76.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does China Resources Boya Bio pharmaceutical Group Co Ltd (300294) generate?
The free cash flow of China Resources Boya Bio pharmaceutical Group Co Ltd is −419M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does China Resources Boya Bio pharmaceutical Group Co Ltd (300294) hold?
China Resources Boya Bio pharmaceutical Group Co Ltd holds more cash than debt, 241M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch China Resources Boya Bio pharmaceutical Group Co Ltd in the live analysis
One click puts China Resources Boya Bio pharmaceutical Group Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026